- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lunar's second-quarter sales jump 62%
Lunar is continuing the strong growth trend in revenues it hasbeen experiencing for the last several quarters. The Madison,WI, manufacturer of bone densitometry equipment said that salesfor the second quarter of 1996 (end-December) jumped 62% to
Lunar is continuing the strong growth trend in revenues it hasbeen experiencing for the last several quarters. The Madison,WI, manufacturer of bone densitometry equipment said that salesfor the second quarter of 1996 (end-December) jumped 62% to $16.9million, compared with $10.5 million in the same period last year.
Lunar's growth is primarily due to higher sales of its DPXbone densitometry scanner, especially in the U.S., according topresident Dr. Richard Mazess, who presented the numbers at theHambrecht & Quist Health Care Conference in San Franciscolast week. Sales of Lunar's high-end Expert system also increased,and the company believes it has resolved the component shortagethat has delayed Expert shipments.
Lunar's net income is also strong. The company expects netincome to be at least 24¢ a share after considering the company'srecent three-for-two stock split. That figure includes legal costsof about 3¢ a share related to its settlement of patent litigationwith Hologic (SCAN 10/11/95).
Mazess also announced that Lunar will spin off its Bone CareInternational subsidiary, which conducts early-stage researchon vitamin-D compounds for osteoporosis and other applications.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
